Liver Cancer, Rectal Cancer, Renal Cancer
Conditions
Brief summary
This is a randomized controlled trial that will be preceded by a safety trial focusing on the safety and efficacy of robotic telesurgery. The hypothesis is that robotic telesurgery has a non-inferior primary endpoint event rate to local laparoscopic surgery.
Detailed description
First, a safety run-in trial for robotic telesurgery will be conducted and evaluated according to 3+3 design. At least 3 patients of each cancer type (including liver cancer,renal cancer and rectal cancer) will be enrolled for robotic telesurgery. If there is a tumor type for which the prior safety trial is terminated, the subsequent randomized controlled trial will not include patients of that type. Second, after passing the safety run-in trial, a randomized controlled trial will be performed. New patients with each cancer type who met the enrollment criteria will be randomly assigned to either the laparoscopic surgery group(control group) or the robotic telesurgery group (intervention group) (84 patients in each group, 168 patients in total) in a 1:1 two-group parallel design.
Interventions
PROCEDURERobotic telesurgery
Telesurgery by domestic surgical robot
PROCEDURELaparoscopic surgery
Local laparoscopic surgery
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Liver Cancer: 1. Age 18 - 75 years. 2. Clinical diagnosis of primary hepatocellular carcinoma or benign tumor such as hepatic adenoma. 3. Patients with hepatocellular carcinoma (BCLC stage 0-B) who were considered suitable for laparoscopic or robotic partial hepatectomy after MDT discussion, or benign tumor such as liver adenoma. 4. ECOG score 0 \ 1. 5. Child-Pugh score 5 \ 7. * Renal cancer: 1. Age 18 - 75 years old. 2. Clinical diagnosis of renal cancer (cT1-T2) or benign tumor such as renal malformation tumor. 3. Patients with benign tumors such as renal cancer (cT1-T2) or renal staggered tumor who were considered amenable to laparoscopic or robotic partial nephrectomy after MDT discussion. 4. ECOG score 0 \ 1. * Rectal cancer: 1. Age 18 - 75 years old. 2. Clinical diagnosis of rectal cancer (Stage I-III). 3. Patients with primary rectal cancer who are considered amenable to laparoscopic or robotic radical rectal adenocarcinoma surgery after MDT discussion. 4. ECOG score 0 \ 1.
Exclusion criteria
* Liver Cancer: 1. Pregnant and lactating women. 2. Combination of other malignant tumors or other malignant tumors within 5 years before enrollment. 3. Recipients of allogeneic organ transplantation. 4. Severe dysfunction of heart, lung, kidney and other organs. * Renal cancer: 1. Pregnant and lactating women. 2. Lymph node metastasis, metastasis to other organs, previous surgical history of renal cancer, or any situation that cannot accept general anesthesia. 3. Combination of other malignant tumors or combination of other malignant tumors within 5 years prior to enrollment. 4. allogeneic organ transplant recipients. 5. Severe dysfunction of heart, lungs, kidneys and other organs. * Rectal cancer: 1. patients with stage IV or complicated disease and emergency surgery. 2. Pregnant and lactating women. 3. Combination of other malignant tumors or combination of other malignant tumors within 5 years before enrollment. 4. Allogeneic organ transplant recipients. 5. Severe dysfunction of heart, lung, kidney and other organs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Surgical complication | One month after surgery | Overall complication events within 30 days of surgery or intraoperative emergency intermediate open surgery events as defined by the Clavin-Dindo grading system |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Surgical time (min) | One month after surgery | Total time from the start of surgery after robotic or laparoscopic installation to the end of incision closure and the surgeon's operating time. |
| Intraoperative blood loss (mL) | One month after surgery | Total bleeding from the start of surgery to the end of incision suturing. |
| Postoperative hospitalization days | One month after surgery | Number of days from the day of surgery to the day of discharge. |
| Physician satisfaction | One month after surgery | A NASA-TLX quantification form was completed by the physician postoperatively. |
| Remote metrics | One month after surgery | Record data related to network transmission end-to-end latency time, jitter, and frame loss. |
Countries
China
Contacts
Primary ContactKuang Ming, PhD
Outcome results
None listed